NASDAQ:ATRS - Antares Pharma Stock Price, Forecast & News

Antares Pharma trades on the NASDAQ under the ticker symbol "ATRS."

Antares Pharma Inc (NASDAQ:ATRS) posted its quarterly earnings data on Tuesday, November, 5th. The specialty pharmaceutical company reported $0.01 EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.02) by $0.03. The specialty pharmaceutical company earned $34.31 million during the quarter, compared to analyst estimates of $26.36 million. Antares Pharma had a negative return on equity of 1.40% and a negative net margin of 0.56%. View Antares Pharma's Earnings History.

Antares Pharma is scheduled to release their next quarterly earnings announcement on Tuesday, March 3rd 2020. View Earnings Estimates for Antares Pharma.

Antares Pharma will be holding an earnings conference call on Tuesday, March 3rd at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Antares Pharma updated its FY 2020 Pre-Market earnings guidance on Monday, January, 27th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $135-155 million, compared to the consensus revenue estimate of $149.16 million.

3 brokerages have issued twelve-month target prices for Antares Pharma's stock. Their forecasts range from $1.99 to $5.65. On average, they anticipate Antares Pharma's stock price to reach $4.21 in the next year. This suggests a possible upside of 19.4% from the stock's current price. View Analyst Price Targets for Antares Pharma.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Antares Pharma in the last year. There are currently 2 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Antares Pharma.

Headlines about ATRS stock have been trending very negative this week, according to InfoTrie Sentiment. The research firm identifies negative and positive news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Antares Pharma earned a daily sentiment score of -3.0 on InfoTrie's scale. They also assigned news coverage about the specialty pharmaceutical company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the company's share price in the near future. View News Stories for Antares Pharma.

Antares Pharma saw a increase in short interest in the month of January. As of January 31st, there was short interest totalling 4,710,000 shares, an increase of 23.3% from the January 15th total of 3,820,000 shares. Based on an average daily volume of 1,860,000 shares, the short-interest ratio is presently 2.5 days. Currently, 3.1% of the shares of the stock are sold short. View Antares Pharma's Current Options Chain.

Some companies that are related to Antares Pharma include Align Technology (ALGN), Cooper Companies (COO), DENTSPLY SIRONA (XRAY), West Pharmaceutical Services (WST), Haemonetics (HAE), ICU Medical (ICUI), Neogen (NEOG), Quidel (QDEL), Merit Medical Systems (MMSI), STAAR Surgical (STAA), Atrion (ATRI), Cerus (CERS), Anika Therapeutics (ANIK), OraSure Technologies (OSUR) and RTI Surgical (RTIX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Antares Pharma investors own include Ballard Power Systems (BLDP), Conatus Pharmaceuticals (CNAT), Novavax (NVAX), Advanced Micro Devices (AMD), NVIDIA (NVDA), Prospect Capital (PSEC), Hi-Crush Partners (HCLP), Canopy Growth (CGC), Macquarie Infrastructure (MIC) and AT&T (T).

Antares Pharma's stock is owned by many different of institutional and retail investors. Top institutional investors include State Street Corp (2.51%), Sargent Investment Group LLC (2.51%), Sargent Investment Group LLC (2.30%), FMR LLC (1.98%), Geode Capital Management LLC (1.30%) and Renaissance Technologies LLC (0.70%). Company insiders that own Antares Pharma stock include Jacques Gonella, Leonard S Jacob, Marvin Samson, Robert F Apple and Thomas J Garrity. View Institutional Ownership Trends for Antares Pharma.

ATRS stock was sold by a variety of institutional investors in the last quarter, including State of New Jersey Common Pension Fund D, Healthcare Value Capital LLC, Bank of America Corp DE, Perkins Capital Management Inc., Principal Financial Group Inc., New York State Common Retirement Fund, Bernardo Wealth Planning LLC and PNC Financial Services Group Inc.. Company insiders that have sold Antares Pharma company stock in the last year include Jacques Gonella, Leonard S Jacob, Marvin Samson, Robert F Apple and Thomas J Garrity. View Insider Buying and Selling for Antares Pharma.

ATRS stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Sargent Investment Group LLC, Goldman Sachs Group Inc., EAM Investors LLC, EAM Global Investors LLC, Sargent Investment Group LLC, Oracle Investment Management Inc. and Marshall Wace LLP. View Insider Buying and Selling for Antares Pharma.

Shares of ATRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ATRS stock can currently be purchased for approximately $3.53.

Antares Pharma has a market capitalization of $576.20 million and generates $63.55 million in revenue each year. The specialty pharmaceutical company earns $-6,510,000.00 in net income (profit) each year or ($0.04) on an earnings per share basis. Antares Pharma employs 165 workers across the globe.View Additional Information About Antares Pharma.

The official website for Antares Pharma is http://www.antarespharma.com/.

Antares Pharma's mailing address is 100 PRINCETON SOUTH SUITE 300, EWING NJ, 08628. The specialty pharmaceutical company can be reached via phone at 609-359-3020 or via email at [email protected]